Prime Medicine, Inc.
NASDAQ:PRMEBiotechnology
Healthcare
$3.84 -1.11%
-$0.04 today
- Market cap
- $698.58M
- Beta
- 2.31
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$1.12
52W Low $1.77High $6.94
Volume 3.99M
Average 2.47M
Income Statement
Follow revenue through to earnings.
Revenue
$4.63M
FY 2025 · Annual
+55.3% YoYOperating Income
-$208.35M
FY 2025 · Annual
Net Income
-$201.14M
FY 2025 · Annual
Income Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 2.98M | 4.63M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 7.32M |
| Gross Profit | 0 | 0 | 0 | 2.98M | (2.69M) |
| Gross Margin | — | — | — | 100.0% | -58.1% |
| Research & Development | 70.55M | 86.73M | 147.91M | 155.29M | 160.64M |
| Selling, General & Admin | 13.92M | 29.82M | 43.39M | 50.16M | 52.35M |
| Operating Expenses | 84.47M | 116.54M | 204.79M | 205.45M | 205.66M |
| Depreciation & Amortization | 568K | 2.22M | 4.65M | 6.13M | 5.38M |
| EBITDA | (165.29M) | (120.55M) | (186.64M) | (189.75M) | (195.76M) |
| EBITDA Margin | — | — | — | -6361.2% | -4226.2% |
| Operating Income | (84.47M) | (116.54M) | (204.79M) | (202.47M) | (208.35M) |
| Operating Margin | — | — | — | -6787.4% | -4498.1% |
| Interest Income | 0 | 0 | 0 | 3.52M | 4.15M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (81.38M) | (6.23M) | 6.38M | 6.59M | 7.21M |
| Income Before Tax | (165.85M) | (122.77M) | (198.41M) | (195.88M) | (201.14M) |
| Pre-Tax Margin | — | — | — | -6566.6% | -4342.4% |
| Income Tax Expense | (486K) | (948K) | (279K) | 0 | 0 |
| Net Income | (165.37M) | (121.82M) | (198.13M) | (195.88M) | (201.14M) |
| Net Margin | — | — | — | -6566.6% | -4342.4% |
| EPS (Basic) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| EPS (Diluted) | (1.92) | (1.46) | (2.18) | (1.65) | (1.35) |
| 95.73M | 97.21M | 90.97M | 118.6M | 148.76M | |
| 95.73M | 97.21M | 90.97M | 118.6M | 148.76M |
PRME Earnings Waterfall · TTM
NASDAQ:PRME · Revenue to Net Income
Key Ratios
EPS$-1.27
Gross Margin-893.8%
Net Margin-5020.8%
P/E Ratio-3.0
P/S Ratio587.0
Analysis
$4.0M of revenue converted into -$198.4M of net income for the selected period. Gross margin is -893.8% and net margin is -5020.8%, showing how much revenue survives after costs and taxes. EPS is $-1.27, tying the income statement back to per-share earnings.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13D/A | SC 13D/A filing | Nov 13, 2026 | |
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 | |
| 8-K | Current report | Nov 12, 2026 |
How much revenue does PRME generate?
Prime Medicine, Inc. (PRME) reported $4.63M of revenue in fiscal 2025.
Is PRME profitable?
Prime Medicine, Inc. (PRME) reported -$201.14M of net income, with a net margin of -4342.4%.
Continue the stock analysis
Jump to another research area for this company.